Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN2 | P17655 | 11/20 | 0.77 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP3 | P08254 | 4/20 | 0.38 |
| ▸ | MMP7 | P09237 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208872 | 0.87 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL930611 | 0.87 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931644 | 0.85 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931561 | 0.83 | CAPN2 (0.56) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL15654382 | 0.83 | CAPN2 (0.63) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL931203 | 0.81 | CAPN2 (0.68) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL8209264 | 0.78 | CAPN2 (1.00) | CAPN2CPB2 | |
| SCHEMBL930579 | 0.77 | CAPN2 (1.00) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL8203817 | 0.77 | CAPN2 (0.98) | CAPN2CPB2MMP1MMP2MMP3 | |
| SCHEMBL12943169 | 0.77 | CAPN2 (0.56) | CAPN2CPB2MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-8710178-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | LINCOLN UNIVERSITY (NZ) | 2014-04-29 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
| WO-2008048121-A2 | MACROCYCLIC CYSTEINE PROTEASE INHIBITORS AND COMPOSITIONS THEREOF | LINCOLN UNIVERSITY (NZ) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN2 4/4885CPB2 36/4885MMP1 307/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | CAPN2 4/4885CPB2 36/4885MMP1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.